fda status bpc-157 compounding pharmacies 2026 Approval 2026: Clinical Trials FDA panel votes to place

That is by design: the protocol treats them as a single recovery unit rather than two separate injection schedules

It's a partnership built on trust, quality, and a shared vision for scientific advancement

The documented research protocol uses a fixed 2,667 mcg (~2.67 mg) total-blend dose = 0.10 mL = 10 units on a U-100 syringe, from an 80 mg vial reconstituted with 3 mL of bacteriostatic water (26.67 mg/mL)

| Target Concentration | BAC Water to Add | Dose per 10 units on syringe | |---------------------|-----------------|------------------------------| | 10mg/ml | 3.0ml | 1.0mg | | 15mg/ml | 2.0ml | 1.5mg | | 6mg/ml | 5.0ml | 0.6mg | **Best for:** Patients on 4-12mg weekly doses who want the best cost-per-milligram value

Davis R

NAD+ / MOTS-C / 5-Amino-1MQ, research compound, third party tested, COA available, Disguised Alpha, Freeze Dried Isolates NAD+ / MOTS-C / 5-Amino-1MQ is commonly positioned around NNMT pathway research, NAD metabolism models, metabolic signaling studies